The Reagent Set,blood Grouping Test, cataloged under National Stock Number 6550-01-542-3777, is classified within Federal Supply Class 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Becton, Dickinson and Company. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6550-01-542-3777 |
| Primary Part Number | 333180 |
| Item Name | Reagent Set,blood Grouping Test |
| FSC / FSG | 6550 / 65 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets |
| Manufacturer | Becton, Dickinson and Company |
| Status | ACTIVE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| 333180 PRIMARY | Becton, Dickinson and Company (USA) |
NSN 6550-01-542-3777 is a Reagent Set,blood Grouping Test, manufactured by Becton, Dickinson and Company, classified under FSC 6550, In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. Status: active.
NSN 6550-01-542-3777 has 1 manufacturer part number on file: 333180 (Becton, Dickinson and Company).
Key specifications for 333180: Special Features: BD ONCOMARK ANTI-HLA-DR FITC/CD13 PE IS INTENDED FOR IN VITRO FLOW CYTOMETRIC IMMUNOPHENOTYPING THIS REAGENT COMBINATION CAN BE USED TO ANALYZE MYELOID LINEAGE DEVELOPMENT;ANTI-HLA-DR AND CD13 ASSAYS ARE USED IN THE DIAGNOSIS OF HEMATOLOGIC DISORDERS;THE ANTIBODY REAGENT IS STABLE UNTIL THE EXPIRATION DATE SHOWN ON THE LABEL WHEN STORED AT 2 TO 8 DEGREE CELSIUS;BD ONCOMARK ANTI-HLA-DR FITC/CD13 PE CAN BE USED FOR IMMUNOPHENOTYPING BY FLOW CYTOMETRY WOTH PERIPHERAL BLOOD AND BONE MARROW ASPIRATES COLLECTED IN EDTA (EG,BD VACUTAINER TUBES);EACH TYPE OF SPECIMEN CAN HAVE DIFFERENT STORAGE CONDITIONS AND LIMITATIONS THAT SHOULD BE CONSIDERED PRIOR TO COLLECTION AND ANALYSIS; Part Name Assigned by Controlling Agency: BD ONCOMARK ANTI-HLA-DR FITC/CD13 PE. 0 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.